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Abstract
Background
The global burden of cervical cancer remains high with the highest morbidity and mortality
rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has
shown to improve treatment outcomes. This is an analysis of the local control results at six
months post-treatment of patients enrolled in an ongoing study investigating the effects of
the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for the treat-
ment of HIV-positive and -negative cervical cancer patients in a low-resource setting.
Methods
This ongoing Phase III randomised controlled trial, conducted at a state hospital in Johan-
nesburg, South Africa, was registered with the appropriate ethics committee. After signing
an informed consent, participants with FIGO stages IIB to IIIB squamous cell carcinoma of
the cervix were randomised to receive chemoradiotherapy with/without mEHT using a
secure online random-sampling tool (stratum: HIV status) accounting for age and stage.
Reporting physicians were blind to treatment allocation. HIV-positive participants on antire-
troviral treatment, or with a CD4 count >200cell/μL were included. mEHT was administered
2/weekly immediately before external beam radiation. The primary end point is local disease
control (LDC) and secondary endpoints are toxicity; quality of life analysis; and two year sur-
vival. We report on six month LDC, including nodes visualised in the radiation field on 18F-
FDG PET/CT (censored for six month survival), and six month local disease free survival
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Results
271 participants were recruited between January 2014 and November 2017, of which 210
were randomised for trial and 202 were available for analysis at six months post-treatment
(mEHT: n = 101; Control: n = 101). Six month LDFS was higher in the mEHT Group (n = 39
[38.6%]), than in the Control Group (n = 20[19.8%]); p = 0.003). LDC was also higher in the
mEHT Group (n = 40[45.5%]) than the Control Group (n = 20[24.1%]); (p = 0.003).
Conclusion
Our results show that mEHT is effective as a chemo-radiosensitiser for cervical cancer,
even in high risk a patients and resource-constrained settings.
Introduction
The global burden of cervical cancer remains high, with 570 000 new cases and 311 000 deaths
estimated to have occurred in 2018. It is the fourth most common cancer, and the cancer with
the fourth highest mortality rate, amongst women. The mortality rate from cervical cancer is
around 3 cases per 100,000 in developed countries and around 18 per 100,000 in developing
countries.[1]
Current standard of care treatment for locally advanced cervical cancer (LACC), which
includes International Federation of Gynaecology and Obstetrics (FIGO) stages IB2 to IVA, is
a combination of chemotherapy (most commonly platinum-based), and radiotherapy (RT).[2]
The treatment of cervical cancer in developing countries is complicated by limited resources,
late stage of disease at presentation,[3] and the high prevalence of Human Immunodeficiency
Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS). Out of 54 African coun-
tries, 28 do not have access to radiotherapy treatments. Of those with access to RT, only 20
have access to brachytherapy (BT).[4] Where RT is available, the planning and delivery tech-
niques are often sub-optimal, with many countries still relying on low energy machines, such
as Cobalt60. There are usually not enough devices or staff to handle the high patient load,
resulting in long waiting times for treatment.[5] The lack of radiology support restricts the
availability of sophisticated planning techniques which require computed tomography (CT) or
magnetic resonance imaging (MRI). Low-resource settings therefore rely on less labour-inten-
sive 2D planning techniques that do not require sophisticated imaging to manage the burden
of the high patient volumes. In our facility patients do have access to BT, however imaging
techniques are not routinely available for the planning of oncology treatments. Treatment out-
comes in low-to-middle-income countries (LMICs) are significantly worse than in less
resource-constrained settings with an estimated 87% of cervical cancer-related deaths occur-
ring in LMICs in 2018.[6] There is a scarcity of information on the outcomes and on the con-
founding prognostic factors unique to LMICs.[7] The protocols and outcome measures used
are often sub-optimal in resource-constrained settings and therefore not comparable to inter-
national literature. For example in Uganda, 316 cervical cancer patients were evaluated and
authors reported that HIV-positive patients (42%) had more than a two-fold higher risk of
death than HIV-negative patients. More than two-thirds of the patients that died in the first
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year, died in the first 6 months post-treatment and only 32% of the HIV-negative and 35% of
the HIV-positive patients were alive at one year post-treatment. While this study did not
report on local control, it does highlight the high mortality rates seen in low-resource settings.
[8] HIV infection is associated with a higher risk of treatment interruptions and residual dis-
ease,[9] a higher risk of not completing the prescribed chemotherapy protocol,[10] and worse
survival rates for cervical cancer patients.[11] The high burden of cervical cancer on already
strained public health systems in Sub-Saharan Africa necessitates the investigation of feasible
chemo-radiosensitisers that are effective, even under such difficult conditions.
Hyperthermia (HT) is well known for its radiosensitising effects and the benefits of its addi-
tion to RT for the management of LACC have been described in two meta-analyses.[12,13]
Hyperthermia (HT) has been investigated as a chemo- or radiosensitiser in numerous studies
on cervical cancer.[14–17] There is evidence that HT may be particularly effective in the treat-
ment of Human Papilloma Virus (HPV) positive cancers as it promotes the degradation of
oncogenic proteins.[18] HT as a radiosensitiser has shown to improve survival and local dis-
ease control (LDC) in LACC patients,[19] however at least one study has reported worse toxic-
ity, with no improvement in local disease control.[20] As a chemo-sensitiser HT has
demonstrated improved outcomes and acceptable toxicity combined with platinum-based
cytotoxic agents in the management of residual or recurrent cervical cancer.[14] Phase I/II
studies have shown that chemoradiotherapy plus HT for the management of LACC is tolerated
well, with no significant increase in treatment related toxicity resulting from the addition of
HT.[21,22] Two Phase III trials were published after recruitment for this study began. One was
closed early due to slow recruitment.[23] Neither of the trials reported an increase in toxicity,
however both trials reported no significant benefit to the addition of HT to chemoradiother-
apy. One study used radiative heating,[23] and one study used a capacitive heating device with
a power output of 800-1500W.[24] however two phase III trials published after recruitment for
this study began, reported no benefit to the addition of HT to chemoradiotherapy.[23,24]
Radiative hyperthermia utilizes external antennas to induce an electromagnetic field using
70 to 120MHz which is coupled into the patient using a water bolus. Complex MRI guided
planning systems and thermometry systems have been developed to support these treatments,
minimize unwanted hot spot formation, and focus the energy on the tumour. Capacitive heat-
ing devices utilize two electrodes to produce an electro-magnetic field by capacitive coupling
with the human body, resulting in heating. Both techniques are widely used clinically.[25]
Challenges with radiative heating include the higher costs, complexity and sophisticated set-
ting required to administer the treatments. Capacitive heating devices in comparison are more
affordable[25] and carry less risk of hot spot formation. Capacitive heating devices frequently
make use of intra-tumoral thermometers or locally applied temperature sensors to confirm
temperatures, although the invasiveness of the procedures carries certain risks. Challenges
associated with capacitive heating involve the effective heating of deep tumours through thick
layers of adipose tissue (>2cm).
Hyperthermia faces challenges with acceptance and consistency in results. Szasz et al pro-
posed a HT technique in which 13.56MHz capacitive-coupled modulated radiofrequency is
applied to selectively target tumour cells based on the differences in the conductivity and per-
mittivity of malignant tissue compared to healthy tissue.[26,27] This selective technique,
known as modulated electro-hyperthermia (mEHT), combines the effects of heating and of
the electric field to sensitise tumours to treatments.[28] The tumour, having different biophysi-
cal properties to healthy tissue, stores a charge thereby heating up selectively. Once the maxi-
mum energy has been absorbed, the excess energy passes through the tumour. This can also be
described as extracellular heating where the extracellular matrix is heated with minimal impact
on the intracellular environment. The device therefore uses the energy (measured in
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Kilojoules) that is put into the system, rather than the temperature, as the measured dose. The
energy output from the first electrode is compared to the energy received by the second elec-
trode. Using algorithms the absorbed energy can be determined[29–31] and the tumour tem-
perature is calculated. This technique therefore does not require intratumoural or MRI
thermo-monitoring systems due to the real-time calculation of temperature by the device
based on the energy dose. Confirmation of the heating capacity of the mEHT has been demon-
strated.[32,33] The techniques is also able to safely heat tumors, regardless of tumour depth or
adipose layer thickness.[30] Hyperthermia interferes with protein synthesis,[26,34] and inhib-
its DNA and RNA synthesis and repair[34,35] by inducing protein aggregation in the nucleus
and changes in the DNA repair foci which inhibit the DNA double-strand break repair pro-
cesses. This is synergistic for RT and for certain cytotoxic agents which cause DNA double-
strand breaks.[36] Hypoxia is a central causative factor for radio-resistance.[37] Heating the
tumour also results in changes in blood perfusion and re-oxygenation. [38] Enhanced perfu-
sion results in improved oxygenation in the target tissue, which enhances the effects of the
Reactive Oxygen Species induced by IR.[39] Increased temperatures result in an increased
immune response at the heated site.[27,40] HT has direct actions on the immune system
through direct heat-mediated cell killing, and indirect actions by modulating the innate and
adaptive immune system.[41] The extra-cellular heating method used by mEHT minimises
the stress on the intracellular environment, reducing the risk of thermo-tolerance. Heating up
the extracellular matrix with low frequency mEHT has only a minor impact on the intracellu-
lar environment and the primary action and heating occurs in the extracellular matrix and at
the cellular membrane.[42] According to research conducted by Andocs et al, cell stress
induced by mEHT results in the generation of DAMP signals and the application of mEHT
could potentially induce local immunogenic cell death.[43] mEHT has also been shown to
induce apoptosis [44] more readily than HT.[45] Andocs et al hypothesise that the energy
absorption at the cell membrane results in a non-homogenous energy distribution causing
damage which activates the cell death-related signalling pathways during mEHT.[45]
mEHT has shown benefits and safety as a chemo-sensitiser for the treatment of recurrent
or residual cervical cancer[17] and the increase in temperature achieved in cervical tumours
using mEHT is similar to the increased temperature reported using other HT methods.[46]
Locations in which the technique has shown safety include the brain,[47] head and neck,[48]
lung,[49] and pancreas,[50] The different dose monitoring system and temperature calcula-
tions means that MRI monitoring is not required. This technique is simple to use in compari-
son to other technologies, making it suitable for investigating as a chemo-radiosensitiser in a
low-resource setting.
In South Africa, cervical cancer is the leading cause of cancer death in women with a life-
time risk of 1 in 44 of developing cervical cancer.[51] According to UNAIDS, in 2017 there
were 36.9 million people infected with the HIV world-wide with an estimated 7.1 million of
those people living in South Africa.[52] The risk of cervical cancer is significantly increased in
HIV-positive patients, likely a result of the of HIV-associated immune suppression[53] and
the subsequent increased risk of chronic HPV infection.[54] This, combined with constrained
resources, makes South Africa a particularly challenging setting in which to test chemo-
radiosensitisers.
We report on an analysis of the local control results at six months post-treatment of patients
enrolled in an ongoing study investigating the effects of the addition of modulated electro-
hyperthermia (mEHT) to chemoradiotherapy for the treatment of LACC patients in a low-
resource setting, with specific interest in the effects on the HIV-positive subgroup. Six month
local disease-free-survival (LDFS) is also reported in order to account for the participants who
did not survive six months post-treatment. To our knowledge, this is the first phase III
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randomised controlled trial (RCT) on the trimodality treatment of cervical cancer using this
form of HT, the first trial to apply HT twice a week for LACC, the first HT trial in Africa, and
the first phase III HT study to include HIV-positive patients in a low-resource setting.
Materials and methods
This a single centre, phase III, randomised controlled (stratum: HIV status; accounting for
stage and age) parallel group trial being conducted at the Charlotte Maxeke Johannesburg Aca-
demic Hospital (CMJAH), a public hospital in Gauteng, South Africa, by the Radiation Sci-
ences department of the University of the Witwatersrand. Approval from the Human
Research Ethics Committee was obtained (M1704133) on 5th June 2012. According to the
requirements of the local ethics board, the trial was registered on the South African National
Clinical Trials Register before recruitment was started (ID: 3012). Registration of the trial Clin-
icalTrials.gov (NCT03332069) was finalised after recruitment began. The authors confirm that
all ongoing and related trials for the intervention are registered on ClinicalTrials.gov.
Eligibility
Patients were recruited by the multi-disciplinary team of gynaecology and oncology specialists
at the CMJAH (January 2014 to December 2017) after undergoing clinical staging according
to FIGO staging criteria,[55] by chest x-ray, ultrasound and physical assessment. Written
informed consent was obtained and participants were referred for additional haematological
investigations (liver function; urea and creatinine levels; full blood count; pregnancy test with
serum βHCG; HIV test; CD4 count if indicated), and a Positron Emission Tomography/Com-
puted Tomography (PET/CT) scan with 18F-Fluorodeoxyglucose (FDG), as part of the screen-
ing process.
Eligibility criteria. Primary, treatment-naïve, histologically confirmed invasive squamous
or adeno-squamous cell carcinoma of the cervix; FIGO stages IIB (with invasion of the distal
half of the parametrium), to IIIB (clinically staged); Eligible for CRT with radical intent;
>18years old; Eastern Cooperative Oncology Group (ECOG) score <2; Creatinine clearance
>60mL/min; Haemoglobin, platelet count and absolute neutrophil count within normal
ranges; HIV positive patients on antiretroviral therapy or with a CD4 count >200cell/μL; Abil-
ity to understand and the willingness to sign a written informed consent document; Life expec-
tancy>12 months; Patients who underwent emergency RT in the form of brachytherapy for
haemostasis prior to enrolment were screened and enrolled provided they met all other eligi-
bility criteria; Body Mass Index (BMI) within normal ranges; Life expectancy of greater than
12 months; Participants with para-aortic and other nodes outside of the radiation field visual-
ised on the 18F-FDG PET/CT scans were included.
Exclusion criteria. Bilateral hydronephrosis; Second primary malignancy; Extra-pelvic
visceral disease visualised on the 18F-FDG PET/CT; Vesicovaginal fistula or vesicorectal fistula
that required a change in treatment protocols; Abnormal liver function tests; Currently preg-
nant or breast feeding; Prior hysterectomy; Prior malignancy treated in the preceding two
years; Cardiovascular disease (excluding controlled hypertension); Acute or life-threatening
infections or medical conditions or life threatening AIDS-defining illnesses other than cervical
cancer; Evidence of resistance to antiretroviral therapy in HIV-positive patients; A medical or
psychiatric illness that preventing the participant from being able to sign an informed consent
or affecting the participant’s ability to comply with the protocol stipulations; Carcinoma of the
cervical stump; Contra-indications to mEHT (pacemakers, large metallic implants in the treat-
ment area, inability to feel temperature in the treatment area, inability to express or vocalise
pain); Any other contraindications to any of the prescribed treatments. Visualisation of para-
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aortic lymph nodes on planning CT was also an exclusion criterion, however patients were not
3D planned.
Randomisation and masking
Once participants passed all screening evaluations, participant data was collected and captured
by the research co-ordinator using REDCap (Research Electronic Data Capture), an online,
secure web based application hosted by the University of the Witwatersrand. The REDCap
stratified on-line software generated random-sampling tool was used to randomise partici-
pants to receive either CRT alone (Control Group) or combined with mEHT (mEHT Group);
stratum: HIV status. Randomisation accounted for age (<30 years; 30–50 years; >50 years),
and FIGO stage (IIB; IIIA; IIIB). Participants were informed in a private consultation by the
research co-ordinator of their treatment group at treatment verification. The research co-coor-
dinator was not involved in the treatment or clinical evaluations. Double blinding of the par-
ticipants was not possible due to logistical challenges such as creating a “placebo treatment” on
the mEHT device in which the participant would feel heat on the surface but not actually be
treated. Clinicians examining the participants during follow-ups were blind to treatment allo-
cation. Physicians reporting on the 18F-FDG PET/CT images were blind to treatment alloca-
tion and did not interact with the participants, eliminating the risk of biased reporting.
Treatment
Chemotherapy (CHT). As per the institutional protocol, two doses of cisplatin (80mg/
m2) administered 21 days apart were planned during external beam radiation (EBRT), subject
to the patient’s ability to receive cisplatin (creatinine clearance >60mL/min; acceptable full
blood count results; acceptable ECOG status). All participants who were treated with cisplatin
received prehydration with normal saline and electrolytes as well as prophylactic antiemetics
intravenously, as per the institutional protocol.
Radiotherapy. A haemoglobin (Hb) level above 10g/dL was required for EBRT and par-
ticipants were transfused as needed. All participants were prescribed RT in the form of EBRT
(50Gy in 25 fractions of 2Gy), and High Dose Rate (HDR) brachytherapy (BT) (3 fractions of
8Gy). The EMBRACE II study aims for an EQD2 dose of>85Gy. However this is not easily
achievable without image guided brachytherapy.[56] The European Society for Medical
Oncology Guidelines on Cervical Cancer management lists the optimal treatment as 80–90Gy
at point A.[2] We planned an intended total equivalent RT dose of 86Gy. Standard planning
for EBRT in our facility is 2D planning, and not the more labour-intensive planning tech-
niques that are standard of care internationally. This is due to the limited staff capacity and
resources available to treat the high volume of gynaecological oncology patients seen each year
and due to the lack of access to imaging techniques, such as MRIs, for planning purposes. Par-
ticipants for this study were planned using virtual simulation and standard fields were placed
but volumes were not contoured as is standard of care for cervical cancer. EBRT was planned
using CT guidance and volumes were determined using bony landmarks to encompass the
entire pelvis including 2cm margins from the pelvic side wall laterally. The superior border
was the midline of L5 and the inferior border extended to 2cm below the tumour. Posterior
border encompasses the sacrum to the third sacral vertebra and the anterior border extended
to the inferior border of the pubic symphysis. A four field box techniques was used for plan-
ning and the dose prescribed was normalized to 95%. The dose to the nodes was the same as
the dose to the centre as it was a homogenous dose distribution to the entire field. 15MV or
18MV photon energy linear accelerators (Siemens Pty, Ltd) were used for the four field tech-
nique. 18F-FDG PET/CT images were additions to the standard protocols with the sole
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purpose of monitoring disease response and the costs of the imaging studies were covered by a
research grant. The 18F-FDG PET/CT images were not used to plan treatments. Para-aortic
nodes seen on PET/CT images were therefore not targeted with EBRT. While extended fields
to include para-aortic nodes significantly decreases the risk of distant metastases and of para-
aortic failure, the effects on overall survival are not yet confirmed[57] and extended fields are
not standard in a resource-constrained setting such as ours.
HDR BT was given as per the institutional protocol. Patients received 36Gy equivalent
(EQD2 –equivalent dose in 2Gy fractions for an alpha-beta ratio of 10), to point A by intracav-
ity BT using standard tandem-ring or tandem-ovoid vaginal applicators (source used: Iridium
192). 2-dimentional calculations were done based on orthogonal x-rays. Chemotherapy was
not permitted on the days that BT was given. A 2D technique was used for the brachytherapy,
due to lack of availability of imaging techniques. If the tumour was confined to the upper
vagina, a ring-tandem applicator was used. Where the tumour extended inferiorly below the
upper half of the vagina, a Joss-Flynn ovoid-tandem applicator was used to cover the whole
extent of the vagina. The lower part of the vagina was kept within rectal tolerance when treat-
ing with a Joss-Flynn ovoid-tandem applicator. Standard IRCU38 bladder and rectal dose
points were calculated for BT. More sophisticated BT techniques require sophisticated imaging
techniques which are not available in low-resource settings. The first BT was planned to be
administered after 10–13 fractions of EBRT with a week between each subsequent BT dose
with the aim of completing all radiation treatments within 52 days.
Hyperthermia. Hyperthermia was delivered via a capacitive heating device (Model:
EHY2000+; Manufacturer: Oncotherm GmbH, Troisdorf, Germany) which uses 13.56MHz
modulated radiofrequency energy. The power was applied using two electrodes, one fixed in
the bed and one in an adjustable arm placed over the treatment area. [58] A 30cm diameter
applicator with electrode was used to cover as much of the pelvic field as possible. Participants
randomised into the mEHT Group received two mEHT treatments (per week at 42.5ºC for a
minimum of 55 minutes, plus the prescribed CRT. A step-up heating protocol was used start-
ing at a power output of 60W and increasing to the planned power over a period of five min-
utes. The planned power for the first treatment was 90W, for the second treatment the
planned power was 110W, and the third and subsequent treatments were planned for 130W.
An average energy dose of 360KJs over ten treatments was planned. mEHT treatments were
administered at least 48 hours apart to reduce the risk of developing thermo-tolerance and
EBRT was administered within 30 minutes of completing mEHT. mEHT was not adminis-
tered on the same day as BT or cisplatin.
Follow-up. Participants were examined, and adverse events were documented, weekly on
treatment and at six weeks, three months and six months post-treatment. Regular full blood
count, renal, and liver function tests were performed. Toxicity was graded according the Com-
mon Toxicity Criteria for Adverse Events (CTCAE) version 4 and toxicities worse than Grade
2 were reported to the investigators. The six month follow-up period extended from February
2014 to August 2018 with the final participant completing treatment in January 2018.
Outcome measures
The primary outcome is LDC at six months post-treatment. Secondary outcomes reported in
this paper include disease pattern analysis, early toxicity, and quality of life. As the participants
were treated with EBRT to the whole pelvis and HT to the pelvis, we considered the entire
region that was within the treatment field, assessing local disease control and not only tumour
response. LDC was therefore considered a failure if the presence of disease in the radiation
field was noted on any one of the evaluation methods post-treatment (Persistent Disease). The
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same method of evaluation is described in the protocols of the multicentre (including our cen-
tre) study by the AIDS Malignancy Consortium (AMC) evaluating 2D planned EBRT, HDR
BT and cisplatin in patients receiving ART (ClinicaTrials.Gov ID:NCT01590017).[59] The
results on LDC from this trial are not yet available. Six month LDFS is also reported, taking
into account death as a possible risk factor.
All participants were planned to have an 18F-FDG PET/CT scan at six months post-treat-
ment to evaluate local disease response and disease patterns presentation using the PERCIST
1.0 criteria (Complete Metabolic Response [CMR] SUV<2.5; Partial Metabolic Response
[PMR] >30% reduction in SUV; Stable Metabolic Disease [SMD] <30% reduction in SUV;
Progressive Metabolic Disease [PMD] increase in SUV).[60]. 13 participants were unable to
have follow-up 18F-FDG PET/CT scans due to poor ECOG status or renal dysfunction and
were evaluated by Fine Needle Aspiration (FNA) of palpable nodes (n = 1), by CT scan (n = 3),
and by clinical examination/PAP smear (n = 9). Evidence of disease on any of the evaluation
methods was regarded as treatment failure. Six month LDFS was analysed according to the
intention to treat principle and was considered a failure if there was a disease-related death or
failure of LDC. We report on the tumour response determined clinically by examination, and
on the level of agreement between tumour response determined by clinical exam and as visual-
ised on 18F-FDG PET/CT images. The early toxicity and quality of life are reported separately.
Further papers on late toxicity and two year survival are planned.
Statistics
The sample size was calculated based on the estimated required sample sizes for a two-sample
comparison of survivors’ functions at two years (statistical power of 90%). We estimated an
expected reduction in mortality at two years of 50%, based on survival of 20% in the control
group and 40% in the experimental group. The statistical significance is defined as a two-sided
alpha<0.05 for a log-rank test, with a constant Hazard ratio of 0.5693. Initially a 15% screening
failure rate was predicted, however the screening failure rate was higher than expected (30%)
and recruitment continued until the pre-determined required number of 200 eligible partici-
pants were enrolled.
Pearson’s Chi squared test and Fisher’s exact tests were used to determine the difference in
frequencies between groups. T-test was used to compare the difference in means between
groups. Logistic regression was used to test if prognostic factors (treatment arm, number of
cisplatin doses; age; overall treatment time; RT dose; CD4 count; Body Mass Index [BMI];
number of mEHT treatments; energy dose administered), significantly predicted outcomes.
The three stratification factors were used in the multivariate logistic regression model. Two
sided p values are reported and p values<0.05 were considered significant. STATA 13.0 Statis-
tics software program (Stata Corporation, College Station, Texas, USA), was used to analyse
the data.
Results
Of 271 screened participants screened between January 2014 and November 2017, 210 were
randomised for trial (Fig 1). The most common reasons for omission of the second cycle of cis-
platin were renal dysfunction (mEHT: n = 19; Control: n = 11) and delayed in the administra-
tion of the first cycle (mEHT: n = 10; Control: n = 7), followed by non-compliance, anaemia,
vomiting and dehydration, sepsis, poor ECOG, immunosuppression and other, including sup-
ply and technical problems. Reasons for all screening failures can be found in S1 Fig. By the
stratification to tumour stage, participant age, and HIV status, the numbers of participants in
each group were balanced. Four randomised participants did not arrive for treatment and no
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further data is available on these participants. They were classified as “lost to follow up”.
Patient, tumour and treatment characteristics were balanced in both treatment groups with no
significant difference in the means or frequencies (Table 1). There were 104 and 102 partici-
pants treated in the mEHT and Control Groups respectively. Four participants could not be
evaluated for LDC at six months post-treatment (in high care with bowel perforation: n = 1;
deceased at home and cause of death unknown: n = 1; too unwell to travel: n = 2).
18FDG-PET/CT scans were conducted at a median of 186 days after completion of all RT treat-
ments (range 154–610 days).
Treatment characteristics
Treatment characteristics are summarised in Table 2. Participants with a decrease in creatinine
clearance to<60mL/min, and in whom measures to improve creatinine clearance failed, or
whose CD4 count decreased to<150cells/uL, were not prescribed the planned cisplatin. Mean
days to complete all radiation was 41.79 days (range 0–97). Six participants in the mEHT
Group and four participants in the Control Group received less than 50Gy EBRT. Three par-
ticipants died during on treatment (mEHT: n = 1; Control: n = 2), two did not arrive for
Fig 1. Trial profile: Consort flow diagram. Abbreviations: mEHT: Modulated Electro-Hyperthermia; LDFS: Local Disease Free Survival.
https://doi.org/10.1371/journal.pone.0217894.g001
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treatment, and two were moved to palliative care due to progression on treatment. Three par-
ticipants who missed three or less fractions of EBRT cited transport difficulties as the reasons.
There were no significant differences in early toxicities between the two groups. The mean
dose of cisplatin received was 1.3. The main reasons for not receiving any cisplatin, a delayed
first dose of cisplatin, or the cancellation of the second dose of cisplatin, are renal dysfunction
(27 participants in the mEHT Group and 22 participants in the Control Group) and anaemia
(n = 7 in both treatment groups). Other reasons for not receiving the required dose of cisplatin
include leucopoenia; dehydration; sepsis; poor ECOG; and a low CD4 count. Three partici-
pants in the mEHT Group had a reduction in power during the mEHT treatments by more
than 20% due to reported pain at the treatment site.
Local disease control and local disease free survival
In total, 202 participants were eligible for six month LDFS analysis (mEHT: n = 101; Control:
n = 101), of which 171 participants (mEHT: n = 88 [87.1%]; Control: n = 83 [82.2%]), were
alive at six months post-treatment. Complete metabolic response (CMR) of all local disease in
the radiation field (LDC) in the participants who survived at six months was significantly asso-
ciated with mEHT administration with a LDC seen in 40[45.5%] of the mEHT Group partici-
pants compared to 20[24.1%] of the Control Group (Pearson’s chi2: p = 0.003). In a
multivariate logistic regression model adjusted for HIV status, FIGO stage and age (Table 3),
Table 1. Participant and treatment characteristics.
OVERALL mEHT Control P Value
n 206 104 [50.5%] 102 [49.5%]
HIV Status Positive 105 [51%] 51 [49%] 54 [53%] p = 575
Negative 101 [49%] 53 [51%] 48 [47%]
FIGO Staging IIB 75 [36%] 40 [38%] 35 [34%] p = 0.825
IIIA 2 [1%] 1 [1%] 1 [1%]
IIIB 129 [63%] 63 [61%] 66 [65%]
ECOG 0 10 [5%] 3 [3%] 7 [7%] p = 0.184
1 196 [95%] 101 [97%] 95 [93%]
Race African 191 [93%] 96 [92%] 95 [93%] p = 0.035
Caucasian 5 [2%] 4 [4%] 1 [1%]
Other 10 [5%] 4 [4%] 6 [6%]
Age [years] Mean 48.6 48.0 49.2 p = 0.388
SD 10.49 10.77 10.22
Range 26–72 26–68 28–72
BMI Mean 27.45 27.81 27.08 p = 0.431
SD 6.68 6.95 6.41
Range 15–49 15–49 15–41.7
Hb [g/dL] Mean 10.95 10.96 10.94 P = 0.924
SD 2.26 2.13 2.39
Range 5.2–16.2 5.7–16.2 5.2–15.2
CD4 count [cells/μL] in HIV positive Mean 550 576.5 524.9 P = 0.315
SD 261.76 251.57 270.97
Range 95–1524 148–1204 95–1524
Abbreviations: mEHT: Modulated electro-hyperthermia; HIV: Human Immunodeficiency Virus; FIGO: International Federation of Gynaecology and Obstetrics;
ECOG: Eastern Cooperative Oncology Group; SD: Standard Deviation; BMI: Body Mass Index; Hb: Haemoglobin.
https://doi.org/10.1371/journal.pone.0217894.t001
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participants in the mEHT Group were significantly more likely to achieve a LDC than partici-
pants in the Control Group (OR: 0.39, 95% CI: 0.20–0.77; p = 0.006). Age was also a predictor
of LDC (OR: 1.04, 95% CI: 1.00–1.08; p = 0.040).
The intention to treat analysis showed a significant association between six month LDFS
and the administration of mEHT (six month LDFS in mEHT Group: n = 39 [38.6%]; six
month LDFS in Control Group: n = 20 [19.8%]; Pearson’s Chi2: p = 0.003). A multivariate
logistic regression model for six month LDFS (Table 4) also showed that participants in the
Table 2. Treatment characteristics.
OVERALL mEHT Control P Value (t-test)
n 206 104 [50.5%] 102 [49.5%]
Total radiation dose Mean 84.3Gy 84.7Gy 84Gy p = 0.624
SD 9.55 7.65 11.18
Range 2-86Gy 20-86Gy 2-86Gy
Total external beam radiation Mean 48.2Gy 49.4Gy 48.0Gy p = 0.724
SD 8.47 7.74 9.19
Range 2-50Gy 20-86Gy 2-50Gy
Days to complete all RT Mean 41.79 41.46 42.13 P = 0.560
SD 8.16 5.88 9.98
Range 0–97 days 12–65 days 0–97 days
No of Cisplatin doses Mean 1.31 1.38 1.25 p = 0.179
SD 0.69 0.67 0.58
0 27 [13%] 11 [11%] 16 [16%]
1 88 [43%] 43 [41%] 45 [44%]
2 91 [44%] 50 [48%] 41 [40%]
Mean 2.88 2.89 2.87 p = 0.778
SD 0.55 0.52 0.58
No of brachytherapy fractions 0 2 [1%] 1 [1%] 1 [1%]
1 2 [1%] 0 [0%] 2 [3%]
2 4 [2%] 3 [4%] 1 [1%]
3 198 [95%] 100 [95%] 98 [95%]
No of mEHT doses Mean 9.09
SD 2.07
Range 1–10
Average administered (KJ) Mean 369.32KJ
SD 71.06
Range 237- 429KJ
Abbreviations: mEHT: Modulated electro-hyperthermia; SD: Standard Deviation; RT: Radiotherapy; KJ: Kilojoules.
https://doi.org/10.1371/journal.pone.0217894.t002
Table 3. Result of Multivariate logistic regression model to predict LDC (adjusted for HIV status, age, and stage).
Variable Odds Ratio
[OR]
P>|z| 95% Confidence interval [CI] range
Arm 0.39 0.006 0.20–0.77
HIV status 0.91 0.781 0.45–1.83
Age (years) 1.04 0.040 1.00–1.08
Stage (II or III) 1.09 0.604 0.78–1.54
Abbreviations: HIV: Human Immunodeficiency Virus
https://doi.org/10.1371/journal.pone.0217894.t003
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mEHT Group were significantly more likely to achieve a six month LDFS than participants in
the Control Group (OR: 0.36, 95% CI: 0.19–0.69; p = 0.002) and age was also a predictor of six
month LDFS (OR: 1.04, 95% CI: 1.00–1.08; p = 0.031).
When analysed by HIV status, six month LDFS occurred in n = 27 [26.5%] of the HIV posi-
tive participants (n = 102), and n = 32 [32%] of the HIV negative participants (n = 100). The
association between HIV status and six month LDFS was not significant (Pearson’s Chi2:
p = 0.338). When analysed by HIV status and treatment group, six month LDFS is higher in
the HIV-positive and -negative participants treated with mEHT, with the highest six month
LDFS seen in the HIV negative mEHT Group. The association between mEHT and six month
LDFS was significant in the HIV-negative participants (Pearson’s Chi2 p = 0.006), but was not
significant in the HIV-positive participants (Pearson’s Chi2 p = 0.174).
Tumour response
CMR of the tumour in the 158 participants (mEHT group: n = 85 [HIV-positive: n = 40; HIV-
negative: n = 45]; Control Group: n = 73 [HIV-positive: n = 35; HIV-negative: n = 38), who
were eligible for 18F-FDG PET/CT scans at six months post-treatment was higher in the
mEHT Group (n = 49 [57.6%]) than in the Control Group (n = 26 [35.6%]), with a significant
association between the metabolic responses and the administration of mEHT (Fischer’s exact:
p = 0.005). These results are represented graphically in Fig 2. Complete metabolic response
was higher in HIV positive participants (n = 40 [53.3%]), than the HIV-negative participants
(n = 35 [42.2%], but this association was not significant (Fisher’s exact: p = 0.340).
In an analysis by HIV status and by treatment group, the CMR was higher in the mEHT
Group than in the Control Group in both HIV-positive and HIV-negative participants. The
association between the CMR rates and mEHT was larger in the HIV-negative participants
(mEHT: n = 25 [56.5%]; Control: n = 10 [26.3%]; Fisher’s exact: p = 0.006), than in the HIV-
positive participants (mEHT: n = 24 [60.0%], Control: n = 16 [45.7%]; Fisher’s exact:
p = 0.196), as seen in Fig 3.
Prognostic variables
The regression analyses show that age, number of cisplatin doses, treatment time, RT dose,
and CD4 count, were not significant predictors of six month LDFS in our study (S1 Table).
In order to assess the efficacy of mEHT further, we considered the effect of BMI[31] (S2
Fig), energy dose (S3 Fig), and number of mEHT treatments on tumour response. Multivariate
regression analyses showed that these variables were not a predictor of six month LDFS (S2
Table).
Disease pattern analysis
In the mEHT Group (n = 95), there were 15[37.5%] participants with extra-pelvic visceral dis-
ease visualised on the post-treatment 18F-FDG PET/CT scans (HIV positive: 9[23%] out of 40;
Table 4. Result of logistic regression analysis to predict six month LDFS (adjusted for HIV status, age, and stage).
Variable Odds Ratio
[OR]
P>|z| 95% Confidence interval [CI] range
Arm 0.36 0.002 0.19–0.69
HIV status 0.91 0.788 0.45–1.83
Age (years) 1.04 0.031 1.00–1.08
Stage (II or III) 1.04 0.830 0.75–1.44
https://doi.org/10.1371/journal.pone.0217894.t004
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HIV negative: n = 6[13%] out of 45). The Control Group (n = 73) had 16[45.7%] participants
with visualised extra-pelvic visceral disease (HIV positive: 7[20%] out of 35; HIV negative:
n = 9[24%] out of 38).The most common site for distant metastasis at six months was lung
(n = 20), followed by liver (n = 12), bone (n = 9); soft tissue (n = 1), and brain (n = 1). Ten par-
ticipants had multiple sites of distant visceral metastases.
54 Participants (64%) from the mEHT Group and 54 participants (74%) from the Control
Group had nodes outside of the radiation field visualised on the pre-treatment 18F-FDG PET/
CT scans. The location of the nodes visualised on the pre-treatment scans are listed in Table 5.
Para aortic nodes were visualised on the pre-treatment scans in 26 of the mEHT Group partici-
pants (25%) and 29 of the Control Group participants (28%). We compared the pre-treatment
18F-FDG PET/CT scans of participants with extra-pelvic nodes to the post-treatment scans of
the same participants in order to determine the response, if any, of the disease outside the radi-
ation field. The percentage of participants who showed a systemic response to treatment, with
resolution of all metabolically active disease (including extra-pelvic nodes which were not in
the RT or mEHT fields, pelvic nodes and the primary tumour), was significantly higher in the
mEHT Group: 24.1% (n = 13; HIV-positive: n = 6; HIV-negative: n = 7), versus the Control
Group: 5.6% (n = 3; HIV-positive: n = 1; HIV-negative: n = 2) (Chi2, Fisher’s exact: p = 0.007).
One participant in each group did not receive cisplatin. In a multivariate analysis of age, cis-
platin doses, total radiation dose and the number of days between the final radiation treatment
and the follow-up 18F-FDG PET/CT, none of the variables were indicators of an abscopal
effect.
Fig 2. Tumour Response as Seen on 18F-FDG PET/CT (PERCIST 1.0) by Treatment Group. mEHT: Fischer’s exact table of association
between all four metabolic responses and mEHT: p = 0.005�. Abbreviations: mEHT: Modulated electro-hyperthermia; CMR: Complete
Metabolic Response; PMR: Partial Metabolic Response; SMD: Stable Metabolic Disease; PMD: Progressed Metabolic Disease.
https://doi.org/10.1371/journal.pone.0217894.g002
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Toxicity
In our study, mEHT did not have any effect on the frequency of CRT-related early toxicities.
The administration of mEHT was not associated with an increased risk in RT delays (OR:
1.614; p = 0.381; 95% CI: 0.553–4.712). Participant tolerance to mEHT treatments was excel-
lent with 95 out of 104 (91.4%) participants receiving eight or more (�80%) of the planned ten
mEHT treatments. The reasons for not receiving more than eight mEHT treatments are adi-
pose burns (n = 2), 1cm blister (n = 1), progressed on treatment (n = 1), moist desquamation
resulting in RT and mEHT delay (n = 2), bleeding resulting in RT and mEHT delay (n = 1),
did not arrive for RT or mEHT (n = 1), deceased on treatment (n = 1). Two participants in the
control group also died during treatment. Eleven (10.6%) mEHT participants reported adverse
events: Grade 1–2 adipose tissue burns (n = 10, 9.5%); grade 1 surface burns (n = 2, 2.0%).
One participant in the Control Group also reported a subcutaneous burn. A multivariate
Fig 3. Tumour Response on 18F-FDG PET/CT (PERCIST 1.0) by Treatment Group and HIV Status. Total participants in each subgroup:
HIV-Positive mEHT: n = 40; HIV-Positive Control: n = 35; HIV-Negative mEHT: n = 45; HIV-Negative Control: n = 38. Abbreviations:
mEHT: Modulated electro-hyperthermia.
https://doi.org/10.1371/journal.pone.0217894.g003
Table 5. Number of patients with nodes visualized in each region on pre-treatment scans.
mEHT (n = 54) Control (n = 54)
Head and Neck 30 [56%] 26 [48%]
Thorax 29 [54%] 30 [56%]
Abdomen 32 [59%] 39 [72%]
Pelvis 43 [80%] 46 [85%]
Abbreviations: mEHT: Modulated Electro-Hyperthermia
https://doi.org/10.1371/journal.pone.0217894.t005
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analysis showed increased BMI (OR: 1.78; p = 0.375; 95% CI: 0.499–6.335), were not predictive
of adverse events associated with mEHT treatments.
Quality of life
At three months post treatment, fatigue and pain were significantly reduced in the mEHT
Group and there was a significant improvement in social functioning (p = 0.049), and emo-
tional functioning (p = 0.017) seen in the mEHT Group. There were no significant differences
in quality of life between the groups while on treatment.
Discussion
Our results show that the addition of mEHT to chemoradiotherapy protocols for the manage-
ment of LACC patients, results in a significantly higher six month LDC and six month LDFS,
in a resource-constrained setting and in immunocompromised patients. Hyperthermia is a
known radiosensitiser[61] and the heating effect of mEHT during the treatments is therefore
likely to be the largest contributor to the improved outcomes seen in patients treated with
mEHT in our study. Another possible contributing factor is the immunomodulating effect of
mEHT described in the literature which may also contribute to the improved outcomes seen
even in patients who are immunocompromised.
Due to resource constraints, the standard of care cisplatin schedule (40mg/m2 weekly), and
standard of care of planning, using at least 3D-conformal radiotherapy (3DCRT) and extended
fields (para-aortic), where indicated, was not used. It is not clear how much 3DCRT planning
and extended radiation fields would improve the results in the treatment groups. Literature
indicates that while extended fields on EBRT to include para-aortic lymph nodes significantly
reduces the risk of distant metastases and the rate of para-aortic failure, the effects on overall
survival are less significant.[57] Resource-constraints also affected factors such as time to com-
plete treatment (listed as technical problems) and timing of the 18F-FDG PET/CT scans in some
cases (PET/CT down time, source supply problems). The control arm in our group had a lower
response than what is generally achieved for LACC patients. Possible reasons include the evalu-
ation of CMR using 18F-FDG PET/CT studies compared to clinical evaluations of tumour
response, a sample taken from a high risk population many of whom may be immunocompro-
mised, and a resource-constrained setting where patient care and available treatments are sub-
standard in comparison to less resource-constrained settings. Under-staging of cervical cancer
patients is a well-documented challenge in low-resource settings where imaging techniques are
not available.[62] There is a high risk that patients in our setting are being under-staged using
only clinical staging methods, compared to the patients staged with imaging studies used in less
resource-constrained settings and it is possible that many of our patients are in fact in Stage IV,
based on the positive lymph nodes seen on pre-treatment 18F-FDG PET/CT scans. The high
rate of screening failure was unexpected and we did not expect that the so many of the patients
were being under-staged and that there would be so many patients with visceral metastases and
bilateral hydronephrosis on PET/CT images. This is an unfortunate challenge in low-resource
setting where imaging studies to adequately stage patients are not routinely available.
The reviewed studies on HT for the treatment of cervical cancer, primary or recurrent, use
local control, and not local disease control, as an outcome measure and the majority of the
studies rely only on the clinical evaluation of local control with only a few using imaging stud-
ies.[14–17,20,22–24,63–67] The results from the two Phase III studies on the addition of HT to
CRT reported a CR rate of 76% versus 86%(p = 0.54)[23] and 77.6% versus 88%(p = 0.192)[24]
in the CRT versus the CRT plus HT groups respectively. In the Harima study[24] CR was
achieved when no tumour was detected on physical examination or MRI, evaluated at one
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month post treatment, although the number of patients evaluated using MRI was not reported.
A multivariable logistic regression model did show that patients receiving CRT combined with
HT in the Harmia study were more likely to have a CR (p = 0.047). Whole pelvis radiotherapy
was applied however local disease control was not reported. The difference between this study
and our study is the type of capacitive heating used and the frequency of HT treatments per
week (one per week in the Harmia study and twice per week in our study). In the Harima
study the tumour temperature was monitored rectally and vaginally, not intratumourally,
compared to the real-time temperature calculations used by the mEHT device. Although 92%
of participants in the Harmia study only received four to six HT treatments, the reasons for
not completing HT (for example patient concerns or HT adverse events) are not given[24].
The compliance to mEHT treatments in our study was very good indicating good tolerance of
the treatment, with more than 90% receiving eight or more mEHT treatments in our study. In
the Phase III study by Flameling et al, the results posted did not include methods of evaluation,
distribution of stages of disease, or patient characteristics. The study was closed prematurely
due to slow recruitment, and was therefore underpowered, making drawing definitive conclu-
sions impossible. In the Flameling study, HT was administered once per week and the primary
tumour response was measured three months post-treatment. [23]
Challenges with clinical staging include the inadequate evaluation of the proximal tumour
extension or side wall invasion, and inaccurate lymph node evaluation (especially deep pelvic
lymph nodes).[68] With a sensitivity and specificity of lymph node evaluation of 100% and
99.6% respectively for nodes larger than 5mm, and the ability to detect metabolic changes before
anatomical changes occur,[69,70] 18F-FDG PET/CT is more effective at detecting lymph node
involvement,[68] distant metastases,[71] and tumour activity.[72] LDC in our study included
lymph nodes within the radiation field as visualised on 18F-FDG PET/CT scans and we report
on the loco-regional metabolic response, not the clinical response of the tumour.
The major challenges with the management of advanced cervical tumors are loco-regional
control and distant metastases. Image guided adaptive brachytherapy (IGABT) has improved
local and pelvic control rates for stage III/IVA disease to between 73% and 86%. Po¨tter et al
report that the improved local and pelvic control compared to historical databases is associated
with an overall survival benefit of around 10%.[56] These results are significantly higher than
those seen in our study. Due to the differences in RT techniques, resources, staffing, patient
characteristics, and confounding factors such as malnutrition and immune suppression, seen
in our setting compared to less resource-constrained settings, a direct comparison of outcomes
between the settings cannot be accurately made.
In our study, BMI and average energy dose were not predictors of six month LDFS, indicat-
ing that the mEHT treatments were able to target tumours regardless of the thickness of the
adipose layer and that the required temperature and effect is still achieved in patients in whom
the applied power needed to be lowered in order to achieve the prescribed treatment duration.
In a phase I/II study investigating the effects of HT combined with CRT for the management
of 68 LACC participants, adverse events directly attributed to HT included superficial burns
(n = 12[18%]) and subcutaneous fatty necrosis (n = 5[7%]).[22] The number of superficial
bones in our study was only two, and each was less than 1cm in diameter.
The significance of the results and benefits of HT for the treatment of LACC in the reviewed
literature varies considerably. One possible reason is the lack of a fixed reference point for tem-
perature and dose calculations, and the different heating methods.[73] Various heating tech-
niques and protocols (treatment duration, frequency, and timing) are used which may
contribute further to the variation in results. The two phase III trials on CRT plus HT which
reported no benefit to the addition of HT, used a protocol of one HT treatment per week plus
weekly cisplatin (40mg/m2),[23,24] compared to our protocols of two mEHT treatments per
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week plus two doses of cisplatin (80g/m2) three weekly. Franckena et al reported that the num-
ber of HT treatments emerged as a predictor of outcomes with patients receiving more than
three HT treatments showing a higher CR.[74] Our study did not show an association between
the number of mEHT treatments and the CR, however the number of participants with three
or less mEHT treatments was only three and the majority (91.3%) of participants could tolerate
eight or more mEHT treatments. The need for mEHT treatment discontinuation was very
low. Although not all participants could receive cisplatin in our study, the number of cisplatin
doses was also not a predictor of outcomes.
Some studies have reported an increase in rates of distant metastases in participants treated
with radiation plus HT.[20] We have not observed the same trend. In our study we observed
the resolution of extra-pelvic nodal disease along with the pelvic disease in some of the partici-
pants. This rate was significantly higher in the mEHT Group. This may be due to the abscopal
effect being potentiated by the addition of mEHT. A further analysis of these participants is
planned.
According to the literature, treatment outcomes for HIV-positive patients are expected to
be worse than in HIV-negative patients.[9–11] However, in our study the HIV-positive partici-
pants had a higher rate of complete metabolic tumour response to treatment than the HIV-
negative participants, although the difference in CMR between the HIV-positive and -negative
participants was not significant (53.3% versus 42.2%; Fisher’s exact: p = 0.340). In a subgroup
analysis of treatment groups in HIV-positive versus HIV-negative participants, the difference
between the Control and mEHT Groups was larger in the HIV-negative participants. HIV-
positive participants in each treatment group had a higher CMR rate at six months. This may
suggest either less of an effect of mEHT in the HIV-positive participants, or a higher radiosen-
sitivity of the tumours in HIV-positive participants. There are indications in the literature that
HIV-positive patients have a higher chromosomal radiosensitivity[75] and this may contribute
to the increased tumour response rates seen in these patients.
The difference between mEHT and other HT techniques is the dosing concept which relies
on the energy dose applied to the patient during the treatment and the temperature is calcu-
lated based on the energy dose applied. Intratumoural or MRI thermo-monitoring systems are
therefore not required, making the technique far simpler and more affordable than other tech-
niques on the market, enabling the integration of the mEHT into the work flow in the
resource-constrained setting. Without the need for increased staff to manage the treatments or
the need for access to MRIs, theatres, or specialists, the use of the heating technique was viable.
Although the device was loaned to the research team for research purposes, should the depart-
ment be in a position to purchase the device, the cost to purchase the device is currently less
than half the price of a BT device and does not require access to imaging techniques that the
more advanced BT systems require. While mEHT is very clearly not a replacement for ade-
quate EBRT and BT planning and treatments, it may be viable technique to improve outcomes
in a setting where sophisticated RT techniques are not likely to be available for some time to
come. A comparison between our results with mEHT and results from the use of mEHT in a
less resource-constrained setting would be merited. Although the response rates varied
between our study and the literature, the difference in CR between the two groups in our study
is 22% and this improvement in outcomes, even in such high risk patients, is a strong indicator
of the potential benefit to the use of mEHT.
Conclusion
This phase III RCT provides the first evidence for the use of mEHT to improve treatment out-
comes when added to CRT for the treatment of LACC. The results offer evidence of efficacy of
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a heating technique that is feasible and can be implemented in a low resource setting in a pop-
ulation sample in whom treatment and management of LACC is particularly challenging. The
results indicate that mEHT can be integrated into the multimodal treatment regimens for
LACC patients treated with radiotherapy with/without cisplatin, improving outcomes and
potentially assisting in alleviating the burden of LACC on healthcare systems. There is also a
potential benefit to the addition of mEHT to CRT for the treatment of LACC in less resource-
constrained settings. A longer follow up period is required to assess the survival benefits and
further papers are planned to report these results. The design of further phase III studies on
mEHT as a chemo- or radiosensitiser for the treatment of other malignancies is warranted.
The potential abscopal effect observed suggests that further investigations into the use of
mEHT combined with immunotherapies are warranted.
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